Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00098800 · ClinicalTrials.gov registry record · NA

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

A NA study, sponsored by University of Arizona.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT00098800 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00098800, a NA study, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer. PURPOSE: This randomized clinical trial is studying how well fenretinide works in preventing ovarian cancer in participants who are at high risk of developing ovarian cancer and planning to undergo surgery to remove the ovaries.

Interventions

  • DRUG fenretinide

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2004-10
Est. Completion 2006-11
Phase NA

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT00098800

The ClinicalTrials.gov registry entry for NCT00098800 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which fenretinide is the first listed.

NCT00098800 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00098800 about?

NCT00098800 is a clinical study titled "Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer. PURPOSE: This randomized clinical trial is studying how well fenretinide works in preventing ovarian cancer in participants who are at high...

What is the current status of trial NCT00098800?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-10. Estimated completion is 2006-11.

What interventions are being tested in trial NCT00098800?

The interventions under investigation include: fenretinide (DRUG).

Who is sponsoring clinical trial NCT00098800?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.